196 related articles for article (PubMed ID: 22848499)
1. Integrative gene expression profiling reveals G6PD-mediated resistance to RNA-directed nucleoside analogues in B-cell neoplasms.
McBrayer SK; Yarrington M; Qian J; Feng G; Shanmugam M; Gandhi V; Krett NL; Rosen ST
PLoS One; 2012; 7(7):e41455. PubMed ID: 22848499
[TBL] [Abstract][Full Text] [Related]
2. The role of miR-122 in the dysregulation of glucose-6-phosphate dehydrogenase (G6PD) expression in hepatocellular cancer.
Barajas JM; Reyes R; Guerrero MJ; Jacob ST; Motiwala T; Ghoshal K
Sci Rep; 2018 Jun; 8(1):9105. PubMed ID: 29904144
[TBL] [Abstract][Full Text] [Related]
3. LncRNA PDIA3P interacts with c-Myc to regulate cell proliferation via induction of pentose phosphate pathway in multiple myeloma.
Yang X; Ye H; He M; Zhou X; Sun N; Guo W; Lin X; Huang H; Lin Y; Yao R; Wang H
Biochem Biophys Res Commun; 2018 Mar; 498(1):207-213. PubMed ID: 29501744
[TBL] [Abstract][Full Text] [Related]
4. Gene knockdown studies revealed CCDC50 as a candidate gene in mantle cell lymphoma and chronic lymphocytic leukemia.
Farfsing A; Engel F; Seiffert M; Hartmann E; Ott G; Rosenwald A; Stilgenbauer S; Döhner H; Boutros M; Lichter P; Pscherer A
Leukemia; 2009 Nov; 23(11):2018-26. PubMed ID: 19641524
[TBL] [Abstract][Full Text] [Related]
5. Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies.
Peterson LF; Sun H; Liu Y; Potu H; Kandarpa M; Ermann M; Courtney SM; Young M; Showalter HD; Sun D; Jakubowiak A; Malek SN; Talpaz M; Donato NJ
Blood; 2015 Jun; 125(23):3588-97. PubMed ID: 25814533
[TBL] [Abstract][Full Text] [Related]
6. Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro.
Ganeshaguru K; Wickremasinghe RG; Jones DT; Gordon M; Hart SM; Virchis AE; Prentice HG; Hoffbrand AV; Man A; Champain K; Csermak K; Mehta AB
Haematologica; 2002 Feb; 87(2):167-76. PubMed ID: 11836167
[TBL] [Abstract][Full Text] [Related]
7. In vitro and In vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts.
Mollinedo F; de la Iglesia-Vicente J; Gajate C; Estella-Hermoso de Mendoza A; Villa-Pulgarin JA; de Frias M; Roué G; Gil J; Colomer D; Campanero MA; Blanco-Prieto MJ
Clin Cancer Res; 2010 Apr; 16(7):2046-54. PubMed ID: 20233887
[TBL] [Abstract][Full Text] [Related]
8. Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling.
Roué G; López-Guerra M; Milpied P; Pérez-Galán P; Villamor N; Montserrat E; Campo E; Colomer D
Clin Cancer Res; 2008 Nov; 14(21):6907-15. PubMed ID: 18980985
[TBL] [Abstract][Full Text] [Related]
9. Mantle cell lymphoma displays a homogenous methylation profile: a comparative analysis with chronic lymphocytic leukemia.
Halldórsdóttir AM; Kanduri M; Marincevic M; Mansouri L; Isaksson A; Göransson H; Axelsson T; Agarwal P; Jernberg-Wiklund H; Stamatopoulos K; Sander B; Ehrencrona H; Rosenquist R
Am J Hematol; 2012 Apr; 87(4):361-7. PubMed ID: 22374828
[TBL] [Abstract][Full Text] [Related]
10. ID1 promotes hepatocellular carcinoma proliferation and confers chemoresistance to oxaliplatin by activating pentose phosphate pathway.
Yin X; Tang B; Li JH; Wang Y; Zhang L; Xie XY; Zhang BH; Qiu SJ; Wu WZ; Ren ZG
J Exp Clin Cancer Res; 2017 Nov; 36(1):166. PubMed ID: 29169374
[TBL] [Abstract][Full Text] [Related]
11. The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group.
Seftel MD; Kuruvilla J; Kouroukis T; Banerji V; Fraser G; Crump M; Kumar R; Chalchal HI; Salim M; Laister RC; Crocker S; Gibson SB; Toguchi M; Lyons JF; Xu H; Powers J; Sederias J; Seymour L; Hay AE
Leuk Lymphoma; 2017 Jun; 58(6):1358-1365. PubMed ID: 27750483
[TBL] [Abstract][Full Text] [Related]
12. Impaired pentose phosphate pathway in the development of 3D MCF-7 cells mediated intracellular redox disturbance and multi-cellular resistance without drug induction.
Wang W; Cai Q; Zhou F; Liu J; Jin X; Ni P; Lu M; Wang G; Zhang J
Redox Biol; 2018 May; 15():253-265. PubMed ID: 29291545
[TBL] [Abstract][Full Text] [Related]
13. BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine.
Zaja F; Di Loreto C; Amoroso V; Salmaso F; Russo D; Silvestri F; Fanin R; Damiani D; Infanti L; Mariuzzi L; Beltrami CA; Baccarani M
Leuk Lymphoma; 1998 Feb; 28(5-6):567-72. PubMed ID: 9613987
[TBL] [Abstract][Full Text] [Related]
14. Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis.
Thieblemont C; Nasser V; Felman P; Leroy K; Gazzo S; Callet-Bauchu E; Loriod B; Granjeaud S; Gaulard P; Haioun C; Traverse-Glehen A; Baseggio L; Bertucci F; Birnbaum D; Magrangeas F; Minvielle S; Avet-Loiseau H; Salles G; Coiffier B; Berger F; Houlgatte R
Blood; 2004 Apr; 103(7):2727-37. PubMed ID: 14630827
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic silencing of miR-26A1 in chronic lymphocytic leukemia and mantle cell lymphoma: Impact on EZH2 expression.
Kopparapu PK; Bhoi S; Mansouri L; Arabanian LS; Plevova K; Pospisilova S; Wasik AM; Croci GA; Sander B; Paulli M; Rosenquist R; Kanduri M
Epigenetics; 2016 May; 11(5):335-43. PubMed ID: 27052808
[TBL] [Abstract][Full Text] [Related]
16. Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes.
Korz C; Pscherer A; Benner A; Mertens D; Schaffner C; Leupolt E; Döhner H; Stilgenbauer S; Lichter P
Blood; 2002 Jun; 99(12):4554-61. PubMed ID: 12036888
[TBL] [Abstract][Full Text] [Related]
17. Hematopoiesis in patients with mature B-cell malignancies is deregulated even in patients with undetectable bone marrow involvement.
Maswabi BC; Molinsky J; Savvulidi F; Zikmund T; Prukova D; Tuskova D; Klanova M; Vockova P; Lateckova L; Sefc L; Zivny J; Trneny M; Klener P
Haematologica; 2017 Apr; 102(4):e152-e155. PubMed ID: 28057744
[No Abstract] [Full Text] [Related]
18. Mantle cell lymphoma-variant Richter syndrome: Detailed molecular-cytogenetic and backtracking analysis reveals slow evolution of a pre-MCL clone in parallel with CLL over several years.
Klener P; Fronkova E; Berkova A; Jaksa R; Lhotska H; Forsterova K; Soukup J; Kulvait V; Vargova J; Fiser K; Prukova D; Alam M; Calvin Lenyeletse Maswabi B; Michalova K; Zemanova Z; Jancuskova T; Pekova S; Trneny M
Int J Cancer; 2016 Nov; 139(10):2252-60. PubMed ID: 27407063
[TBL] [Abstract][Full Text] [Related]
19. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.
Chiron D; Dousset C; Brosseau C; Touzeau C; Maïga S; Moreau P; Pellat-Deceunynck C; Le Gouill S; Amiot M
Oncotarget; 2015 Apr; 6(11):8750-9. PubMed ID: 25797245
[TBL] [Abstract][Full Text] [Related]
20. Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma.
Gonzalez-Santamarta M; Quinet G; Reyes-Garau D; Sola B; Roué G; Rodriguez MS
Adv Exp Med Biol; 2020; 1233():153-174. PubMed ID: 32274756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
